14Sep/22

ADC Panoramic Overview-Linker

September 14, 2022ReviewADC linkerbioadc

The linker is not only the molecular part of the covalent connection between the antibody and the small molecular payload but also a key element with design properties in targeted drug therapy.Read More…

10Sep/22

Recap of the 13th World ADC San Diego: Discovering Innovative Conjugate!

September 10, 2022Uncategorized13th Annual World ADC, ADC Event, antibody-drug conjugatebioadc

Creative Biolabs, one of the industry-pioneering CROs holding specialties in bioconjugate, participated in the 13th Annual World ADC Summit last week and announced the successful accomplishment of its journey in San Diego.Read More…

31Jul/22

About ADCs Payloads: Innovative Drug

July 31, 2022ReviewADCs Payloads, Amatoxin, Non-cleavable Linkers, Thailanstatin Abioadc

Innovative Drugs Apoptosis inducer (Bcl-xL inhibitor) The overexpression of anti-apoptotic Bcl-2 family members (including Bcl-xL) is one of the mechanisms by which cancer cells acquire apoptosis resistance. Drugs that block the BH3-bindingRead More…

31Jul/22

About ADCs Payloads: DNA-damaging Drug

July 31, 2022ReviewADCs Payloads, Calicheamicins, DNA-damaging Drugs, Duocarmycinbioadc

DNA-damaging Drugs Pyrrolobenzodiazepine and Indolinobenzodiazepine Pyrrolobenzodiazepines (PBD) is a kind of natural product with antineoplastic activity. Their mode of action is selective alkylation in a small groove of DNA, in which guanineRead More…

31Jul/22

About ADCs Payloads: Microtubule-destroying Drug

July 31, 2022ReviewADCs Payloads, Auristatin F, DM4, Microtubule-destroying drugsbioadc

Antibody-drug conjugate (ADC) is formed by linking monoclonal antibodies targeting specific antigens with small molecular cytotoxic drugs through linkers, which have both the strong killing effect of traditional small molecule chemotherapy andRead More…

27Jun/22

NEJM: ADC Drug for Advanced Breast Cancer Treatment Shows Amazing Effect

June 27, 2022Antibody-drug Conjugates ResearchADC toxins, ADCs, HER2bioadc

Breast cancer is the most common cancer among women. In 2020, breast cancer has replaced lung cancer as the number one cancer in the world. The latest global cancer burden data forRead More…

22Apr/22

The Review of New Drug Conjugates

April 22, 2022ReviewABC, ADC, AECbioadc

With the approval of a number of ADC drugs around the world since 2019, conjugated drugs have developed into one of the hottest tracks in the pharmaceutical industry. Not only traditional ADCRead More…

28Dec/21

New structures to resolve the instability of Maleimide joint

December 28, 2021Antibody-drug Conjugates ManufacturingADC, ADC linker, Hydrolyzed Maleimide linkerbioadc

An ADC consists of an antibody and toxin bridged by a linker that affects the coupling stability to some extent and has an important influence on ADC efficacy. The premature release ofRead More…

24Nov/21

Ushering in a “Raging” Era—Fiercely Competitive Phase III ADCs (part I)

November 24, 2021ReviewADC Therapy, CEACAM5, DM4, Phase III ADCsbioadc

An antibody-drug conjugate (ADC) is composed of an antibody, a chemical linker, and a small molecular payload, and takes advantage of the specific targeting binding ability of antibody to transport cytotoxic payloadRead More…

08Jul/21

Analytical methods of average drug to antibody ratio (DAR) of antibody-drug conjugates

July 8, 2021ReviewADCs, DAR analysis, HIC, HILIC, LC-MS, Ultraviolet spectrophotometrybioadc

Antibody-drug conjugate (ADC) is a new type of biological targeting drug for the cancer treatment, which perfectly combines the high specificity of antibody and the strong lethal power of cytotoxin. With theRead More…